{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Couper K"],"funding":["National Institute for Health Research (NIHR)"],"pagination":["100544"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10801302"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17"],"pubmed_abstract":["Aims
The PARAMEDIC-3 trial evaluates the clinical and cost-effectiveness of an intraosseous first strategy, compared with an intravenous first strategy, for drug administration in adults who have sustained an out-of-hospital cardiac arrest.Methods
PARAMEDIC-3 is a pragmatic, allocation concealed, open-label, multi-centre, superiority randomised controlled trial. It will recruit 15,000 patients across English and Welsh ambulance services. Adults who have sustained an out-of-hospital cardiac arrest are individually randomised to an intraosseous access first strategy or intravenous access first strategy in a 1:1 ratio through an opaque, sealed envelope system. The randomised allocation determines the route used for the first two attempts at vascular access. Participants are initially enrolled under a deferred consent model.The primary clinical-effectiveness outcome is survival at 30-days. Secondary outcomes include return of spontaneous circulation, neurological functional outcome, and health-related quality of life. Participants are followed-up to six-months following cardiac arrest. The primary health economic outcome is incremental cost per quality-adjusted life year gained.Conclusion
The PARAMEDIC-3 trial will provide key information on the clinical and cost-effectiveness of drug route in out-of-hospital cardiac arrest.Trial registration: ISRCTN14223494, registered 16/08/2021, prospectively registered."],"journal":["Resuscitation plus"],"pubmed_title":["Route of drug administration in out-of-hospital cardiac arrest: A protocol for a randomised controlled trial (PARAMEDIC-3)."],"pmcid":["PMC10801302"],"funding_grant_id":["NIHR131105"],"pubmed_authors":["Deakin CD","Chowdhury L","Slowther AM","Sprauve L","Rees N","Wood S","Long J","Mason J","Lang N","Nwankwo H","Williams J","Starr K","Charlton K","Norman C","Nolan JP","Coppola A","Mellett-Smith A","Wright A","Walker A","Tibbetts B","Spaight R","Foster T","Wiles J","Ji C","Osborne R","Michelet F","Quinn T","Jackson M","Kearney J","Evans C","Smyth MA","Brown M","Whitley GA","Fothergill R","Bell S","Pocock H","Bradley G","Couper K","Lall R","Brown S","Perkins GD"],"additional_accession":[]},"is_claimable":false,"name":"Route of drug administration in out-of-hospital cardiac arrest: A protocol for a randomised controlled trial (PARAMEDIC-3).","description":"Aims
The PARAMEDIC-3 trial evaluates the clinical and cost-effectiveness of an intraosseous first strategy, compared with an intravenous first strategy, for drug administration in adults who have sustained an out-of-hospital cardiac arrest.Methods
PARAMEDIC-3 is a pragmatic, allocation concealed, open-label, multi-centre, superiority randomised controlled trial. It will recruit 15,000 patients across English and Welsh ambulance services. Adults who have sustained an out-of-hospital cardiac arrest are individually randomised to an intraosseous access first strategy or intravenous access first strategy in a 1:1 ratio through an opaque, sealed envelope system. The randomised allocation determines the route used for the first two attempts at vascular access. Participants are initially enrolled under a deferred consent model.The primary clinical-effectiveness outcome is survival at 30-days. Secondary outcomes include return of spontaneous circulation, neurological functional outcome, and health-related quality of life. Participants are followed-up to six-months following cardiac arrest. The primary health economic outcome is incremental cost per quality-adjusted life year gained.Conclusion
The PARAMEDIC-3 trial will provide key information on the clinical and cost-effectiveness of drug route in out-of-hospital cardiac arrest.Trial registration: ISRCTN14223494, registered 16/08/2021, prospectively registered.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2024-11-06T01:38:05.542Z","creation":"2024-11-06T01:38:05.542Z"},"accession":"S-EPMC10801302","cross_references":{"pubmed":["38260121"],"doi":["10.1016/j.resplu.2023.100544"]}}